UNSPSC 51184001: Acetohexamide

This classification denotes an anti-diabetic agent with the molecular formula C15H20N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QGC8W08I6I, chemically known as urea, 1-((p-acetylphenyl)sulfonyl)-3-cyclohexyl- but more generally known as acetohexamide, which bears US NIH Compound Identifier 1989. European Medicines Agency schedules Acetohexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05223MIG.

UNSPSC 51184001 Acetohexamide, a Commodity code, encompasses diabetes medications and other prescription pharmaceuticals that state and local health agencies, departments of corrections, Medicaid programs, and public health systems procure through cooperative purchasing vehicles and multistate frameworks. The code captures individual active pharmaceutical ingredients and branded or generic formulations distributed to public facilities, clinics, and beneficiary populations. State and local governments acquire these products almost exclusively through established wholesaler networks and multistate cooperative agreements rather than direct manufacturer relationships, with purchasing coordinated through procurement offices that aggregate demand across multiple jurisdictions to achieve volume discounts and standardized pricing structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response deadline March 26, 2026. The solicitation targets manufacturers capable of supplying comprehensive product portfolios with specific National Drug Codes (NDC) through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation emphasizes price competitiveness at 75 percent weight, compliance with cGMP and Drug Supply Chain Security Act (DSCSA) certification, EDI capability, and contractual relationships with at least two of the three authorized wholesalers. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, submit pricing in flat price, net price (NF30, NF60, NF90), or WAC-minus formats, and accept a 3 percent administrative fee on all contract purchases. The contract term spans two years for new responders with optional extensions, and MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs across participating jurisdictions including Oregon.